ReviewLasers in medical science2026
Port-wine stains: molecular drivers, translational models, and emerging theragnostic directions.
Review in Lasers in medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Port-wine stains (PWS), also termed capillary malformations, are congenital, progressive microvascular anomalies that can cause lifelong cosmetic and psychosocial burden and may signal syndromic involvement such as Sturge-Weber syndrome (SWS). We performed a focused evidence synthesis integrating mechanistic literature on somatic mosaicism and vascular remodeling with clinical evidence from randomized trials, observational cohorts, and quantitative-imaging studies. Key endpoints and theragnostic concepts were summarized to inform trial design and individualized treatment strategies. Somatic activating variants in GNAQ and related signaling networks drive endothelial dysfunction, aberrant vessel maturation, and lesion progression. Pulsed-dye laser(PDL) remains the global first-line modality, but response is heterogeneous and often incomplete, particularly in thick or nodular lesions. Hematoporphyrin monomethyl ether (hemoporfin)-mediated photodynamic therapy(PDT) shows high efficacy for selected phenotypes but carries distinct adverse-event profiles. Emerging theragnostics-including dynamic optical coherence tomography(D-OCT) and computational reconstruction-enable noninvasive quantification of vessel depth and caliber, supporting phenotype-guided parameter selection and objective response assessment. A mechanistically anchored, phenotype-informed framework that integrates molecular drivers with quantitative vascular imaging can accelerate precision strategies for PWS, improve endpoint rigor, and guide next-generation combination and targeted therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.